Bruker (BRKR)
Market Price (12/26/2025): $47.85 | Market Cap: $7.3 BilSector: Health Care | Industry: Health Care Equipment
Bruker (BRKR)
Market Price (12/26/2025): $47.85Market Cap: $7.3 BilSector: Health CareIndustry: Health Care Equipment
Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.
| Megatrend and thematic driversMegatrends include Biotechnology & Genomics, Precision Medicine, and Advanced Materials. Themes include Advanced Diagnostics, Show more. | Weak multi-year price returns2Y Excs Rtn is -81%, 3Y Excs Rtn is -105% | Expensive valuation multiplesP/EBITPrice/EBIT or Price/(Operating Income) ratio is 98x, P/CFOPrice/(Cash Flow from Operations). CFO is cash before capital expenditures. is 77x |
| Weak revenue growthRev Chg QQuarterly Revenue Change % is -0.5% | ||
| Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -4.1% | ||
| Key risksBRKR key risks include [1] a high vulnerability to shifts in academic and government research funding and [2] the continuous innovation pressures and market expansion challenges inherent to its high-end equipment business model. |
| Megatrend and thematic driversMegatrends include Biotechnology & Genomics, Precision Medicine, and Advanced Materials. Themes include Advanced Diagnostics, Show more. |
| Weak multi-year price returns2Y Excs Rtn is -81%, 3Y Excs Rtn is -105% |
| Expensive valuation multiplesP/EBITPrice/EBIT or Price/(Operating Income) ratio is 98x, P/CFOPrice/(Cash Flow from Operations). CFO is cash before capital expenditures. is 77x |
| Weak revenue growthRev Chg QQuarterly Revenue Change % is -0.5% |
| Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -4.1% |
| Key risksBRKR key risks include [1] a high vulnerability to shifts in academic and government research funding and [2] the continuous innovation pressures and market expansion challenges inherent to its high-end equipment business model. |
Why The Stock Moved
Qualitative Assessment
AI Analysis | Feedback
The stock of Bruker (BRKR) experienced a notable upward movement, by approximately 42%, in the period from late August 2025 to late December 2025. This rebound followed a significant drop in its stock price after the Q2 2025 earnings report. The key factors contributing to this appreciation include:1. Better-than-Expected Q3 2025 Earnings: Bruker reported third-quarter 2025 non-GAAP earnings per share (EPS) of $0.45, significantly beating the analyst consensus estimate of $0.34 by 32%. While reported revenue saw a slight year-over-year decrease of 0.5%, it still surpassed analyst expectations, signaling a stronger performance than anticipated.
2. Strategic Cost-Saving Initiatives: The company announced and continued progress on a substantial cost-saving initiative aimed at reducing annual costs by $100 million to $120 million in fiscal year 2026. This initiative is expected to lead to significant margin expansion and double-digit non-GAAP EPS growth in the coming year, providing a positive outlook for future profitability.
Show more
Stock Movement Drivers
Fundamental Drivers
The 56.5% change in BRKR stock from 9/25/2025 to 12/25/2025 was primarily driven by a 56.9% change in the company's P/S Multiple.| 9252025 | 12252025 | Change | |
|---|---|---|---|
| Stock Price ($) | 30.75 | 48.12 | 56.50% |
| Change Contribution By | LTM | LTM | |
| Total Revenues ($ Mil) | 3442.80 | 3438.90 | -0.11% |
| P/S Multiple | 1.35 | 2.12 | 56.88% |
| Shares Outstanding (Mil) | 151.60 | 151.80 | -0.13% |
| Cumulative Contribution | 56.50% |
Market Drivers
9/25/2025 to 12/25/2025| Return | Correlation | |
|---|---|---|
| BRKR | 56.5% | |
| Market (SPY) | 4.9% | 28.1% |
| Sector (XLV) | 16.2% | 57.6% |
Fundamental Drivers
The 14.4% change in BRKR stock from 6/26/2025 to 12/25/2025 was primarily driven by a 14.8% change in the company's P/S Multiple.| 6262025 | 12252025 | Change | |
|---|---|---|---|
| Stock Price ($) | 42.07 | 48.12 | 14.38% |
| Change Contribution By | LTM | LTM | |
| Total Revenues ($ Mil) | 3446.10 | 3438.90 | -0.21% |
| P/S Multiple | 1.85 | 2.12 | 14.77% |
| Shares Outstanding (Mil) | 151.60 | 151.80 | -0.13% |
| Cumulative Contribution | 14.38% |
Market Drivers
6/26/2025 to 12/25/2025| Return | Correlation | |
|---|---|---|
| BRKR | 14.4% | |
| Market (SPY) | 13.1% | 18.8% |
| Sector (XLV) | 16.6% | 48.5% |
Fundamental Drivers
The -17.0% change in BRKR stock from 12/25/2024 to 12/25/2025 was primarily driven by a -21.6% change in the company's P/S Multiple.| 12252024 | 12252025 | Change | |
|---|---|---|---|
| Stock Price ($) | 57.96 | 48.12 | -16.98% |
| Change Contribution By | LTM | LTM | |
| Total Revenues ($ Mil) | 3241.30 | 3438.90 | 6.10% |
| P/S Multiple | 2.71 | 2.12 | -21.59% |
| Shares Outstanding (Mil) | 151.50 | 151.80 | -0.20% |
| Cumulative Contribution | -16.98% |
Market Drivers
12/25/2024 to 12/25/2025| Return | Correlation | |
|---|---|---|
| BRKR | -17.0% | |
| Market (SPY) | 15.8% | 41.8% |
| Sector (XLV) | 13.3% | 55.3% |
Fundamental Drivers
The -26.9% change in BRKR stock from 12/26/2022 to 12/25/2025 was primarily driven by a -45.3% change in the company's P/S Multiple.| 12262022 | 12252025 | Change | |
|---|---|---|---|
| Stock Price ($) | 65.82 | 48.12 | -26.89% |
| Change Contribution By | LTM | LTM | |
| Total Revenues ($ Mil) | 2505.80 | 3438.90 | 37.24% |
| P/S Multiple | 3.88 | 2.12 | -45.29% |
| Shares Outstanding (Mil) | 147.80 | 151.80 | -2.71% |
| Cumulative Contribution | -26.95% |
Market Drivers
12/26/2023 to 12/25/2025| Return | Correlation | |
|---|---|---|
| BRKR | -34.1% | |
| Market (SPY) | 48.3% | 39.5% |
| Sector (XLV) | 18.5% | 51.3% |
Price Returns Compared
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Total [1] | |
|---|---|---|---|---|---|---|---|
| Returns | |||||||
| BRKR Return | 7% | 55% | -18% | 8% | -20% | -18% | -4% |
| Peers Return | 37% | 44% | -16% | -7% | 2% | 2% | 58% |
| S&P 500 Return | 16% | 27% | -19% | 24% | 23% | 18% | 115% |
Monthly Win Rates [3] | |||||||
| BRKR Win Rate | 50% | 92% | 58% | 50% | 50% | 25% | |
| Peers Win Rate | 65% | 82% | 42% | 47% | 45% | 47% | |
| S&P 500 Win Rate | 58% | 75% | 42% | 67% | 75% | 73% | |
Max Drawdowns [4] | |||||||
| BRKR Max Drawdown | -38% | -2% | -42% | -19% | -34% | -50% | |
| Peers Max Drawdown | -26% | -6% | -31% | -29% | -8% | -25% | |
| S&P 500 Max Drawdown | -31% | -1% | -25% | -1% | -2% | -15% | |
[1] Cumulative total returns since the beginning of 2020
[2] Peers: TMO, DHR, A, WAT, RVTY. See BRKR Returns vs. Peers.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2025 data is for the year up to 12/24/2025 (YTD)
How Low Can It Go
| Event | BRKR | S&P 500 |
|---|---|---|
| 2022 Inflation Shock | ||
| % Loss | -46.5% | -25.4% |
| % Gain to Breakeven | 86.8% | 34.1% |
| Time to Breakeven | 528 days | 464 days |
| 2020 Covid Pandemic | ||
| % Loss | -41.5% | -33.9% |
| % Gain to Breakeven | 71.1% | 51.3% |
| Time to Breakeven | 250 days | 148 days |
| 2018 Correction | ||
| % Loss | -27.2% | -19.8% |
| % Gain to Breakeven | 37.4% | 24.7% |
| Time to Breakeven | 50 days | 120 days |
| 2008 Global Financial Crisis | ||
| % Loss | -80.2% | -56.8% |
| % Gain to Breakeven | 404.8% | 131.3% |
| Time to Breakeven | 696 days | 1,480 days |
Compare to ABT, DHR, A, WAT, DAVI
In The Past
Bruker's stock fell -46.5% during the 2022 Inflation Shock from a high on 9/3/2021. A -46.5% loss requires a 86.8% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth over time.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
Bruker Corporation develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States and internationally. The company operates through three segments: Bruker Scientific Instruments (BSI) Life Science, BSI NANO, and Bruker Energy & Supercon Technologies. It offers life science tools, and single and multiple modality systems; life science mass spectrometry; MALDI Biotyper rapid pathogen identification platform and related test kits, DNA test strips, and fluorescence-based polymerase chain reaction technology; genotype and fluorotype molecular diagnostics kits; research, analytical, and process analysis instruments and solutions; SARS-CoV 2 testing for the diagnosis of COVID-19 infection; and Fluorotyper-SARS-CoV 2 plus kits. It also provides range of portable analytical and bioanalytical detection systems, and related products; X-ray instruments; analytical tools for electron microscopes, as well as handheld, portable, and mobile X-ray fluorescence spectrometry instruments; atomic force microscopy instrumentation; non-contact nanometer resolution solution topography; and automated X-ray metrology, automated AFM defect-detection, and photomask repair and cleaning equipment. In addition, the company offers advanced optical fluorescence microscopy instruments; products and services to support the multi-omics needs of researchers in translational research, drug, and biomarker discovery; superconducting materials, such as metallic low temperature superconductors; devices and complex tools based on metallic low temperature superconductors; and non-superconducting high technology tools, such as synchrotron and beamline instrumentation. Bruker Corporation has a collaboration with Newomics Inc. on a LC-MS platform for drug discovery. The company was incorporated in 1991 and is headquartered in Billerica, Massachusetts.
AI Analysis | Feedback
Here are 1-3 brief analogies to describe Bruker (BRKR):
A more specialized Thermo Fisher Scientific, focused on high-end analytical instruments for scientific research.
The Intuitive Surgical for scientific research labs, building critical diagnostic and analytical instruments.
The ASML for scientific discovery, developing indispensable high-tech instruments for cutting-edge research.
AI Analysis | Feedback
Bruker (BRKR) primarily provides advanced scientific instruments and solutions for molecular and materials research, along with related services:
- Mass Spectrometers: Advanced instruments used for identifying and quantifying molecules in complex samples across various scientific disciplines.
- NMR Spectrometers: High-resolution systems for determining the structure, dynamics, and interactions of molecules, crucial for drug discovery and materials science.
- X-ray Diffraction (XRD) Systems: Equipment for analyzing the atomic and molecular structure of crystalline materials.
- X-ray Fluorescence (XRF) Spectrometers: Instruments for elemental analysis and material characterization across industries.
- Atomic Force Microscopes (AFM): Tools for visualizing and manipulating matter at the nanoscale, essential for surface science and nanotechnology.
- Preclinical Imaging Systems: Specialized MRI, PET, and CT instruments designed for in-vivo research on small animals.
- Infrared and Raman Spectrometers: Analytical instruments used for chemical identification, material analysis, and quality control.
- Service and Support: Comprehensive technical assistance, maintenance, training, and application support for their range of scientific instruments.
AI Analysis | Feedback
Bruker (BRKR) primarily sells its advanced scientific instruments and analytical solutions to other companies and institutions, rather than directly to individuals. Due to the diverse and fragmented nature of its customer base across various global industries and research sectors, Bruker does not typically have a few specific "major customers" (i.e., individual companies that account for a significant portion of its revenue, requiring disclosure) in the traditional sense. Instead, its sales are distributed among a wide array of entities within key market segments.
Therefore, while specific customer company names and their symbols cannot be listed, the major categories of customers that Bruker serves are:
- Pharmaceutical and Biotechnology Companies: These companies utilize Bruker's systems for various applications including drug discovery, development, quality control, and manufacturing processes for drugs, vaccines, and other biologics.
- Academic and Government Research Institutions: Universities, national laboratories, and government-funded research centers worldwide rely on Bruker's instrumentation for fundamental and applied scientific research across disciplines such as life sciences, materials science, chemistry, and physics.
- Industrial and Applied Markets: This broad category includes companies in sectors such as chemicals, petrochemicals, advanced materials, food and beverage, environmental monitoring, and forensics. These customers use Bruker's solutions for quality control, process optimization, product development, and regulatory compliance.
- Clinical and Diagnostic Laboratories / Hospitals: Bruker's products are increasingly used in clinical microbiology, pathology, molecular diagnostics, and pre-clinical research within hospitals and specialized diagnostic laboratories for improving patient care and diagnostics.
AI Analysis | Feedback
nullAI Analysis | Feedback
Frank H. Laukien, Chairman, President and Chief Executive Officer
Dr. Frank H. Laukien has served as Bruker's Chairman, President, and Chief Executive Officer since February 1991, and is also the company's largest stockholder. He is the son of Günther Laukien, who founded Bruker in 1960. Dr. Laukien earned a Bachelor of Science degree in physics from MIT in 1984 and a PhD in chemical physics from Harvard University in 1988. His career includes lecturing in NMR and mass spectrometry at the University of Bremen, Germany, and serving as a part-time professor at the Institute of Mass Spectrometry of the University of Amsterdam, Netherlands. He also served on the Board of the Analytical, Life Science & Diagnostics Association (ALDA), including one year as chairman. He took Bruker public in 2000. Dr. Laukien is an angel investor in biotherapeutics and space exploration startups, and is the executive chairman of Gauss Fusion GmbH, a startup focused on commercializing nuclear fusion.
Gerald N. Herman, Executive Vice President & Chief Financial Officer
Mr. Gerald N. Herman has been Bruker's Chief Financial Officer since June 2018, after initially being appointed Interim CFO in March 2018. He joined Bruker in 2016 as Vice President and Corporate Controller. Before joining Bruker, Mr. Herman held senior executive positions at various global publicly traded companies. This includes serving as Corporate Vice President - Clinical Operations of PAREXEL International from 2014 to February 2016, and as Corporate Vice President & Controller-Finance of PAREXEL from 2008 to 2013. Prior to 2008, he was Vice President - Corporate Controller of Presstek, Inc.. He also worked in financial, consulting, and accounting roles, including as a Senior Manager at Arthur Andersen LLP from 1979 to 1987. Mr. Herman is a Certified Public Accountant (CPA) and holds an MBA from the University of Chicago and a Master of Science in Taxation from Bentley University.
Mark R. Munch, President of Bruker Nano Group and Corporate Executive Vice President
Dr. Mark R. Munch has served as President of Bruker Nano, Inc. since October 2010. In March 2021, he also assumed the role of Chief Executive Officer of Acuity Spatial Genomics, a Bruker majority investment. Before joining Bruker Nano, Inc., Dr. Munch was Executive Vice President of Veeco Instruments Inc. from February 2008 to October 2010. His previous experience includes serving as Senior Vice President of Coherent, Inc. from February 2006 to January 2008, and as President and Chief Executive Officer of Cooligy, Inc., a subsidiary of Emerson Electric, from 2004 to 2006.
Juergen Srega, President, Bruker CALID Group and Bruker Daltonics Division
Mr. Juergen Srega has been the Group President of Bruker CALID Group at Bruker Corporation since January 2013.
Falko Busse, President, Bruker BioSpin Group
Dr. Falko Busse has been President of the Bruker BioSpin Group since May 2018, overseeing its global operations. He was Deputy President of the Bruker BioSpin Group from October 2017 until his appointment as President. From March 2017 to September 2017, Dr. Busse served as Executive Vice President of Research and Development, Operations, and Marketing for the Bruker BioSpin Group. He joined the Bruker BioSpin Group in June 2015, initially as Executive Vice President of Research and Development. Dr. Busse holds a B.A. and a Ph.D. in Physics from Rheinische Friedrich-Wilhelms-Universität Bonn.
AI Analysis | Feedback
Bruker (BRKR) faces several key risks to its business operations and financial performance:
- Heavy Reliance on Academic and Government Research Funding: A significant portion of Bruker's revenue is derived from academic and government research funding. This reliance makes the company highly vulnerable to budget cuts, funding delays, and shifts in research priorities, such as the NIH funding cuts, which have been noted as a "structural risk" and a "dire weakness."
- Innovation and Market Expansion Risks for High-End Equipment: Bruker specializes in high-end scientific instruments and analytical solutions. This business model entails inherent risks related to continuous innovation, as 70% of its income comes from equipment sales, making it exposed to the success or failure of new technologies. Challenges also arise from regulatory hurdles, intense price competition, and a potential market shift towards lower-cost analytical solutions.
- Adverse Macroeconomic Conditions and Geopolitical Tensions: The company operates in a global market and is susceptible to broader macroeconomic uncertainties, including inflation, higher interest rates, and geopolitical tensions. These factors can lead to cautious investment decisions, delayed stimulus for high-end research instrumentation in key markets (like China), and global tariff considerations, all of which can impact demand for Bruker's products and overall market stability.
AI Analysis | Feedback
null
AI Analysis | Feedback
Bruker (symbol: BRKR) operates in several key markets for its scientific instruments and analytical and diagnostic solutions. The addressable market sizes for its main products and services are identified as follows:
Mass Spectrometry (MS)
- The global mass spectrometry market was valued at approximately USD 6.93 billion in 2024 and is projected to reach USD 11.72 billion by 2033.
- Another estimate places the global mass spectrometry market at USD 6.4 billion in 2024, with a projection to reach USD 14.6 billion by 2035.
- North America currently holds a significant share, accounting for about 41.7% of the global mass spectrometry market in 2024.
Nuclear Magnetic Resonance (NMR) Spectroscopy
- The global nuclear magnetic resonance spectroscopy market size was estimated at USD 724.7 million in 2023 and is projected to reach USD 1.08 billion by 2030.
- In 2024, the global nuclear magnetic resonance spectroscopy market size was approximately USD 1.59 billion and is predicted to grow to about USD 2.73 billion by 2034.
- North America dominated the global NMR spectroscopy market in 2024 with a 46% share. Europe was the largest revenue-generating market in 2023.
X-ray Diffraction (XRD)
- The global X-Ray Diffraction Analysis market size is predicted to grow from US$ 769 million in 2025 to US$ 1048 million by 2031.
- Another report values the global X-ray diffractometer market at USD 778.59 million in 2023, expecting it to reach USD 1061.14 million by 2032.
- The global X-ray diffractometer (XRD) market was valued at approximately USD 2.3 billion in 2023 and is projected to reach around USD 3.5 billion by 2032.
- North America dominated the global diffractometer market in 2023, and the United States leads the X-Ray Diffraction Analysis market globally. Asia Pacific is expected to witness the highest growth rate.
Atomic Force Microscopy (AFM)
- The global Atomic Force Microscopy Market was valued at USD 513.6 million in 2024 and is projected to grow to USD 762.2 million by 2030.
- Another estimate states the global atomic force microscopy market size was USD 514.85 million in 2024 and is anticipated to register a CAGR of 7.4% from 2025 to 2034.
- North America held the largest share in this market in 2024. Asia-Pacific is also expected to grow at the fastest rate.
Microscopy (General)
- The global microscopy market size is expected to be worth around US$ 27.8 billion by 2034, up from US$ 13.6 billion in 2024.
- In 2023, the global microscope market size was estimated at USD 11.94 billion and is projected to reach USD 20.43 billion by 2030.
- North America led the global microscopy market in 2023, accounting for over 39.4% share with a revenue of US$ 5.4 billion. Asia Pacific dominated the overall microscope market in 2023 with a share of 37.1%.
Life Science Tools
- The global life science tools market size was estimated at USD 167.82 billion in 2024 and is projected to reach USD 401.01 billion by 2033.
- Another source indicates the life science tools industry is projected to rise from USD 138.52 billion in 2024 to USD 470.20 billion by 2034.
- North America dominated the global life science tools market in 2024 with the largest revenue share of 42.56%.
Analytical Instrumentation
- The Global Analytical Instrumentation Market was valued at USD 60.4 billion in 2024 and is anticipated to increase to USD 103.3 billion by 2035.
- Another estimate for the global analytical instrumentation market size was USD 60 billion in 2024, with projections to grow at a CAGR of 6.5% from 2025 to 2034.
- North America held the largest share of the global analytical instrumentation market in 2024, representing 46.95% of the overall revenue.
AI Analysis | Feedback
Bruker Corporation (BRKR) is expected to drive future revenue growth over the next 2-3 years through several key initiatives and market trends:
- New Product Launches and Innovation: Bruker is focusing on breakthrough research advancements and new technology, particularly in diagnostic tools. The company has recently launched new products in spatial biology, proteomics, and multiomics solutions, which are anticipated to strengthen its position in the post-genomics market and enhance its leadership in drug discovery and disease biology research.
- Expansion into Emerging Markets: A significant driver is Bruker's international expansion strategy, specifically targeting emerging markets. These regions are experiencing rising demand for advanced healthcare solutions and increased investment in healthcare and research infrastructure, which Bruker aims to capitalize on to tap into new revenue sources.
- Strategic Acquisitions and Partnerships: Bruker has engaged in strategic collaborations, including a recent partnership with a major pharmaceutical giant. This collaboration is expected to strengthen Bruker's market presence and create opportunities for new ventures within the healthcare sector. Strategic acquisitions are also viewed as a way to broaden product offerings and penetrate new markets.
- Recovery in Key Market Segments: Despite facing some challenges, Bruker anticipates a recovery in demand from the academic, government, and biopharma sectors. There are signs of improving funding trends in the US academic market, and the pharmaceutical sector has shown recovery. The company has also noted positive growth in organic scientific instrument orders from China, supported by early signs of stimulus funding.
AI Analysis | Feedback
Share Repurchases
- Bruker authorized a new share repurchase program of up to $500 million in May 2023, extending through May 2025.
- The company also authorized a $500 million share repurchase program in May 2021 for a two-year period.
- Cash flow statements indicate significant share repurchases, including approximately $152.3 million in 2023, $263.1 million in 2022, and $153.3 million in 2021.
Share Issuance
- Bruker's shares outstanding have shown some increases in recent years; for example, they were 0.152 billion for the quarter ending June 30, 2025, reflecting a 2.5% increase year-over-year.
- Overall, the number of shares outstanding increased by 2.43% in one year as of a recent report.
Outbound Investments
- Bruker has pursued an aggressive acquisition strategy, completing 7 acquisitions in 2024 and 6 in 2023.
- Significant acquisitions include ELITechGroup for approximately $944 million (EUR 870 million) in February 2024 (closed May 2024), enhancing its molecular diagnostic systems business.
- Other notable acquisitions include NanoString Technologies for $393 million in April 2024 to boost spatial transcriptomics, and PhenomeX for $108 million in August 2023 to enter single-cell biology research tools. These investments aim to expand technologies in high-growth areas like spatial biology, proteomics, molecular diagnostics, and lab automation.
Capital Expenditures
- Bruker's capital expenditures were approximately $115.3 million in 2024, $106.9 million in 2023, and $129.2 million in 2022.
- The company anticipates capital expenditures of $80 million to $90 million for the full fiscal year 2025.
- Capital expenditures are primarily focused on investments that enable innovation and sustainable growth, including its Project Accelerate 2.0 initiatives, and advancements in areas like post-genomics and semiconductor metrology.
Latest Trefis Analyses
| Title | |
|---|---|
| ARTICLES |
Trade Ideas
Select ideas related to BRKR. For more, see Trefis Trade Ideas.
| Date | Ticker | Company | Category | Trade Strategy | 6M Fwd Rtn | 12M Fwd Rtn | 12M Max DD |
|---|---|---|---|---|---|---|---|
| 11142025 | CRL | Charles River Laboratories International | Dip Buy | DB | FCFY OPMDip Buy with High FCF Yield and High MarginBuying dips for companies with high FCF yield and meaningfully high operating margin | 21.1% | 21.1% | -3.7% |
| 11142025 | GDRX | GoodRx | Dip Buy | DB | CFO/Rev | Low D/EDip Buy with High Cash Flow MarginsBuying dips for companies with significant cash flows from operations and reasonable debt / market cap | -6.7% | -6.7% | -11.8% |
| 11142025 | ASTH | Astrana Health | Dip Buy | DB | FCF Yield | Low D/EDip Buy with High Free Cash Flow YieldBuying dips for companies with significant free cash flow yield (FCF / Market Cap) and reasonable debt / market cap | 16.7% | 16.7% | -5.5% |
| 11142025 | SGRY | Surgery Partners | Dip Buy | DB | FCF Yield | Low D/EDip Buy with High Free Cash Flow YieldBuying dips for companies with significant free cash flow yield (FCF / Market Cap) and reasonable debt / market cap | 2.3% | 2.3% | -1.4% |
| 11072025 | TFX | Teleflex | Dip Buy | DB | FCFY OPMDip Buy with High FCF Yield and High MarginBuying dips for companies with high FCF yield and meaningfully high operating margin | 11.8% | 11.8% | -5.1% |
| 10312024 | BRKR | Bruker | Dip Buy | DB | P/E OPMDip Buy with Low PE and High MarginBuying dips for companies with tame PE and meaningfully high operating margin | -30.4% | -30.9% | -48.0% |
Research & Analysis
Invest in Strategies
Wealth Management
Peer Comparisons for Bruker
| Peers to compare with: |
Financials
| Median | |
|---|---|
| Name | |
| Mkt Price | 184.89 |
| Mkt Cap | 30.9 |
| Rev LTM | 5,193 |
| Op Inc LTM | 1,152 |
| FCF LTM | 877 |
| FCF 3Y Avg | 935 |
| CFO LTM | 1,144 |
| CFO 3Y Avg | 1,189 |
Growth & Margins
| Median | |
|---|---|
| Name | |
| Rev Chg LTM | 4.7% |
| Rev Chg 3Y Avg | 0.1% |
| Rev Chg Q | 4.7% |
| QoQ Delta Rev Chg LTM | 1.1% |
| Op Mgn LTM | 18.7% |
| Op Mgn 3Y Avg | 19.3% |
| QoQ Delta Op Mgn LTM | -0.3% |
| CFO/Rev LTM | 21.4% |
| CFO/Rev 3Y Avg | 21.0% |
| FCF/Rev LTM | 17.1% |
| FCF/Rev 3Y Avg | 16.9% |
Valuation
| Median | |
|---|---|
| Name | |
| Mkt Cap | 30.9 |
| P/S | 5.3 |
| P/EBIT | 29.0 |
| P/E | 34.3 |
| P/CFO | 27.3 |
| Total Yield | 2.6% |
| Dividend Yield | 0.1% |
| FCF Yield 3Y Avg | 3.1% |
| D/E | 0.1 |
| Net D/E | 0.1 |
Returns
| Median | |
|---|---|
| Name | |
| 1M Rtn | -4.9% |
| 3M Rtn | 26.9% |
| 6M Rtn | 14.8% |
| 12M Rtn | 1.7% |
| 3Y Rtn | -1.8% |
| 1M Excs Rtn | -5.8% |
| 3M Excs Rtn | 21.9% |
| 6M Excs Rtn | 1.9% |
| 12M Excs Rtn | -14.1% |
| 3Y Excs Rtn | -82.4% |
Comparison Analyses
Segment Financials
Assets by Segment| $ Mil | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Bruker Scientific Instruments (BSI) BioSpin, Bruker Scientific Instruments (BSI) Chemicals, Applied | 4,111 | 3,508 | |||
| Bruker Energy & Supercon Technologies (BEST) | 186 | 111 | 98 | 89 | 65 |
| Eliminations and other | -47 | ||||
| Corporate, eliminations and other | -8 | -8 | -4 | -5 | |
| Bruker Scientific Instruments Life Science, Bruker Scientific Instrument(BSI) NANO &Corporate | 3,560 | 2,964 | 2,712 | ||
| Total | 4,250 | 3,612 | 3,650 | 3,049 | 2,772 |
Price Behavior
Price Behavior
| Market Price | $48.12 | |
| Market Cap ($ Bil) | 7.3 | |
| First Trading Date | 08/04/2000 | |
| Distance from 52W High | -23.2% | |
| 50 Days | 200 Days | |
| DMA Price | $43.11 | $38.97 |
| DMA Trend | down | up |
| Distance from DMA | 11.6% | 23.5% |
| 3M | 1YR | |
| Volatility | 44.4% | 52.7% |
| Downside Capture | 7.54 | 123.75 |
| Upside Capture | 216.11 | 87.44 |
| Correlation (SPY) | 29.6% | 41.8% |
BRKR Betas & Captures as of 11/30/2025
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
| 1M | 2M | 3M | 6M | 1Y | 3Y | |
|---|---|---|---|---|---|---|
| Beta | 0.89 | 0.72 | 0.79 | 1.04 | 1.11 | 1.07 |
| Up Beta | 0.71 | 0.95 | 1.32 | 0.62 | 1.23 | 1.13 |
| Down Beta | -0.01 | 1.38 | 0.70 | 0.93 | 1.09 | 1.06 |
| Up Capture | 401% | 218% | 177% | 149% | 78% | 64% |
| Bmk +ve Days | 12 | 25 | 38 | 73 | 141 | 426 |
| Stock +ve Days | 13 | 26 | 36 | 69 | 128 | 371 |
| Down Capture | -50% | -91% | -15% | 101% | 109% | 104% |
| Bmk -ve Days | 7 | 16 | 24 | 52 | 107 | 323 |
| Stock -ve Days | 6 | 15 | 26 | 56 | 120 | 377 |
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
Based On 1-Year Data
| Comparison of BRKR With Other Asset Classes (Last 1Y) | |||||||
|---|---|---|---|---|---|---|---|
| BRKR | Sector ETF | Equity | Gold | Commodities | Real Estate | Bitcoin | |
| Annualized Return | -12.5% | 16.4% | 19.2% | 71.9% | 8.9% | 6.0% | -10.1% |
| Annualized Volatility | 52.4% | 17.3% | 19.5% | 19.3% | 15.3% | 17.1% | 35.0% |
| Sharpe Ratio | -0.07 | 0.72 | 0.78 | 2.69 | 0.36 | 0.18 | -0.12 |
| Correlation With Other Assets | 55.5% | 42.1% | -2.7% | 7.1% | 37.2% | 16.8% | |
ETFs used for asset classes: Sector ETF = XLV, Equity = SPY, Gold = GLD, Commodities = DBC, Real Estate = VNQ, and Bitcoin = BTCUSD
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 5-Year Data
| Comparison of BRKR With Other Asset Classes (Last 5Y) | |||||||
|---|---|---|---|---|---|---|---|
| BRKR | Sector ETF | Equity | Gold | Commodities | Real Estate | Bitcoin | |
| Annualized Return | -2.1% | 8.6% | 14.9% | 18.7% | 11.7% | 4.8% | 32.7% |
| Annualized Volatility | 38.7% | 14.5% | 17.1% | 15.5% | 18.7% | 18.9% | 48.7% |
| Sharpe Ratio | 0.05 | 0.41 | 0.70 | 0.97 | 0.51 | 0.17 | 0.60 |
| Correlation With Other Assets | 53.1% | 48.4% | 8.7% | 4.7% | 39.3% | 21.0% | |
ETFs used for asset classes: Sector ETF = XLV, Equity = SPY, Gold = GLD, Commodities = DBC, Real Estate = VNQ, and Bitcoin = BTCUSD
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 10-Year Data
| Comparison of BRKR With Other Asset Classes (Last 10Y) | |||||||
|---|---|---|---|---|---|---|---|
| BRKR | Sector ETF | Equity | Gold | Commodities | Real Estate | Bitcoin | |
| Annualized Return | 7.9% | 9.8% | 14.7% | 14.9% | 6.9% | 5.2% | 69.3% |
| Annualized Volatility | 36.2% | 16.6% | 18.0% | 14.8% | 17.6% | 20.8% | 55.8% |
| Sharpe Ratio | 0.32 | 0.48 | 0.70 | 0.83 | 0.31 | 0.22 | 0.90 |
| Correlation With Other Assets | 57.6% | 55.7% | 5.7% | 14.0% | 42.8% | 15.7% | |
ETFs used for asset classes: Sector ETF = XLV, Equity = SPY, Gold = GLD, Commodities = DBC, Real Estate = VNQ, and Bitcoin = BTCUSD
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Earnings Returns History
Expand for More| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| 11/3/2025 | -0.6% | 2.5% | 22.9% |
| 7/21/2025 | -12.1% | 3.4% | -15.6% |
| 5/7/2025 | 3.3% | -1.8% | -4.5% |
| 2/13/2025 | -1.0% | 2.5% | -11.0% |
| 11/5/2024 | 3.4% | -4.5% | 0.3% |
| 8/6/2024 | -2.2% | -4.9% | 1.4% |
| 5/2/2024 | -11.3% | -6.7% | -17.1% |
| 2/13/2024 | 8.8% | 14.9% | 31.2% |
| ... | |||
| SUMMARY STATS | |||
| # Positive | 11 | 12 | 13 |
| # Negative | 13 | 12 | 11 |
| Median Positive | 3.4% | 3.0% | 7.7% |
| Median Negative | -2.5% | -4.7% | -11.0% |
| Max Positive | 8.8% | 14.9% | 31.2% |
| Max Negative | -12.1% | -9.2% | -30.6% |
SEC Filings
Expand for More| Report Date | Filing Date | Filing |
|---|---|---|
| 9302025 | 11052025 | 10-Q 9/30/2025 |
| 6302025 | 8062025 | 10-Q 6/30/2025 |
| 3312025 | 5072025 | 10-Q 3/31/2025 |
| 12312024 | 3032025 | 10-K 12/31/2024 |
| 9302024 | 11072024 | 10-Q 9/30/2024 |
| 6302024 | 8092024 | 10-Q 6/30/2024 |
| 3312024 | 5102024 | 10-Q 3/31/2024 |
| 12312023 | 2292024 | 10-K 12/31/2023 |
| 9302023 | 11092023 | 10-Q 9/30/2023 |
| 6302023 | 8092023 | 10-Q 6/30/2023 |
| 3312023 | 5102023 | 10-Q 3/31/2023 |
| 12312022 | 3012023 | 10-K 12/31/2022 |
| 9302022 | 11042022 | 10-Q 9/30/2022 |
| 6302022 | 8052022 | 10-Q 6/30/2022 |
| 3312022 | 5062022 | 10-Q 3/31/2022 |
| 12312021 | 2282022 | 10-K 12/31/2021 |
External Quote Links
| Y Finance | Barrons |
| TradingView | Morningstar |
| SeekingAlpha | ValueLine |
| Motley Fool | Robinhood |
| CNBC | Etrade |
| MarketWatch | Unusual Whales |
| YCharts | Perplexity Finance |
| FinViz |
Prefer one of these to Trefis? Tell us why.